Reports of dual PI3K/mTOR inhibitors (Gedatolisib, Omipalisib, Apitolisib, and others) currently in Phase I or II clinical stages indicate that none have received FDA approval for cancer therapy 96, 110-113. Here, PIK3CD is linked to cancer.